Olle Larsson

Publications
Public outreach and news

Articles

Article: CLINICAL CANCER RESEARCH. 2024;30(12):2647-2658

Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma

Ofverholm I; Wallander K; Haglund C; Chellappa V; Wejde J; Gellerbring A; Wirta V; Renevey A; Caceres E; Tsagkozis P; Mayrhofer M; Papakonstantinou A; Linder-Stragliotto C; Branstrom R; Larsson O; Lindberg J; Lin Y; de Flon FH
Article: MOLECULAR CANCER RESEARCH. 2023;21(6):535-547

Interdependence of SS18-SSX-driven YAP1 and b-Catenin Activation in Synovial Sarcoma

Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
Article: CELLULAR ONCOLOGY. 2022;45(3):399-413

SS18-SSX drives CREB activation in synovial sarcoma

Cyra M; Schulte M; Berthold R; Heinst L; Jansen E-P; Gruenewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
Article: MODERN PATHOLOGY. 2021;34(11):2020-2027

TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma

Zhang Y; Chen Y; Yang C; Seger N; Hesla AC; Tsagkozis P; Larsson O; Lin Y; Haglund F
Article: ONCOLOGY REPORTS. 2021;46(2):168

Nuclear IGF1R interacts with NuMA and regulates 53BP1-dependent DNA double-strand break repair in colorectal cancer

Yang C; Zhang Y; Segar N; Huang C; Zeng P; Tan X; Mao L; Chen Z; Haglund F; Larsson O; Chen Z; Lin Y
Article: MOLECULAR ONCOLOGY. 2020;14(5):1101-1117

Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency

Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
Article: PLOS ONE. 2020;15(7):e0236291

Nuclear IGF1R interact with PCNA to preserve DNA replication after DNA-damage in a variety of human cancers

Yang C; Zhang Y; Chen Y; Ragaller F; Liu M; Corvigno S; Dahlstrand H; Carlson J; Chen Z; Nasman A; Waraky A; Lin Y; Larsson O; Haglund F
Article: SCIENTIFIC REPORTS. 2019;9(1):19704

Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone

Isfort I; Elges S; Cyra M; Berthold R; Renner M; Mechtersheimer G; Aman P; Larsson O; Ratner N; Hafner S; Simmet T; Schliemann C; Rossig C; Dirksen U; Gruenewald I; Wardelmann E; Huss S; Hartmann W; Trautmann M
Article: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2019;12(1):80

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK⁺ T-cell lymphoma

George B; George SK; Shi W; Haque A; Shi P; Eskandari G; Axelson M; Larsson O; Kaseb AO; Amin HM
Article: CLINICAL CANCER RESEARCH. 2019;25(12):3718-3731

SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma

Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Gruenewald I; Huss S; Esseling E; Mikesch J-H; Hafner S; Simmet T; Wozniak A; Schoffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Article: MODERN PATHOLOGY. 2018;31(12):1834-1841

hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality

Lin Y; Seger N; Chen Y; Hesla AC; Wejde J; Ghaderi M; Tsagkozis P; Larsson O; Haglund F
Article: JOURNAL OF CLINICAL PATHOLOGY. 2018;71(9):832-839

Telomerase promoter mutations and copy number alterations in solitary fibrous tumours

Lin Y; Seger N; Tsagkozis P; Hesla AC; Ghaderi M; Chen Y; Ehnman M; Warsito D; Wejde J; Larsson O; Haglund F
Article: EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2018;179(2):85-95

Characterization of an activating R1353H insulin-like growth factor 1 receptor variant in a male with extreme tall height

Lin Y; van Duyvenvoorde HA; Liu H; Yang C; Warsito D; Yin C; Kant SG; Haglund F; Wit JM; Larsson O
Article: CANCER CYTOPATHOLOGY. 2018;126(1):36-43

FNA cytology of solitary fibrous tumors and the diagnostic value of STAT6 immunocytochemistry

Tani E; Wejde J; Astrom K; Wingmo I-L; Larsson O; Haglund F
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2017;292(44):18227-18239

Nuclear insulin-like growth factor 1 receptor phosphorylates proliferating cell nuclear antigen and rescues stalled replication forks after DNA damage

Waraky A; Lin Y; Warsito D; Haglund F; Aleem E; Larsson O
Article: ONCOTARGET. 2017;8(46):81501-81510

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response

Aiken R; Axelson M; Harmenberg J; Klockare M; Larsson O; Wassberg C
Article: JOURNAL OF CELLULAR PHYSIOLOGY. 2017;232(10):2722-2730

SUMO-modified insulin-like growth factor 1 receptor (IGF-1R) increases cell cycle progression and cell proliferation

Lin Y; Liu H; Waraky A; Haglund F; Agarwal P; Jernberg-Wiklund H; Warsito D; Larsson O
Article: FRONTIERS IN PHARMACOLOGY. 2017;8:726

Phenotypic Screen Identifies a Small Molecule Modulating ERK2 and Promoting Stem Cell Proliferation

Yin C; Fufa T; Chandrasekar G; Aeluri M; Zaky V; Abdelhady S; Rodriguez AB; Jakobsson J; Varnoosfaderani FS; Mahalingam J; Liu J; Larsson O; Hovatta O; Gaunitz F; Gondor A; Andang M; Kitambi SS
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2016;478(4):1575-1581

Downregulation of IGF-1 receptor occurs after hepatic linage commitment during hepatocyte differentiation from human embryonic stem cells

Waraky A; Aleem E; Larsson O
Article: ONCOTARGET. 2016;7(27):42288-42302

Nuclearly translocated insulin-like growth factor 1 receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2 expression via Brg1 chromatin remodeling protein

Warsito D; Lin Y; Gnirck A-C; Sehat B; Larsson O
Article: JOURNAL OF PATHOLOGY CLINICAL RESEARCH. 2016;2(2):59-71

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.

Angelika Ihle M; Merkelbach-Bruse S; Hartmann W; Bauer S; Ratner N; Sonobe H; Nishio J; Larsson O; Åman P; Pedeutour F; Taguchi T; Wardelmann E; Buettner R; Schildhaus H-U
Article: ACTA ONCOLOGICA. 2016;55(2):140-148

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial

Ekman S; Harmenberg J; Frodin J-E; Bergstrom S; Wassberg C; Eksborg S; Larsson O; Axelson M; Jerling M; Abrahmsen L; Hedlund A; Alvfors C; Stahl B; Bergqvist M
Article: BIOCHEMISTRY. 2015;54(33):5157-5166

The Nucleus-Localized Epidermal Growth Factor Receptor Is SUMOylated

Packham S; Lin Y; Zhao Z; Warsito D; Rutishauser D; Larsson O
Article: MEDICAL ONCOLOGY. 2015;32(7):188

Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells

Stromberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Article: LABORATORY INVESTIGATION. 2015;95(6):603-609

RNA sequencing of sarcomas with simple karyotypes: identification and enrichment of fusion transcripts

Hofvander J; Tayebwa J; Nilsson J; Magnusson L; Brosjo O; Larsson O; von Steyern FV; Domanski HA; Mandahl N; Mertens F
Article: ONCOGENE. 2015;34(17):2227-2238

Nuclear translocation of IGF-1R via p150^Glued and an importin-β/RanBP2-dependent pathway in cancer cells

Packham S; Warsito D; Lin Y; Sadi S; Karlsson R; Sehat B; Larsson O
Article: MEDICAL ONCOLOGY. 2015;32(4):129

A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.

Holgersson G; Bergström S; Harmenberg J; Ringbom M; Klockare M; Jerling M; Ekman S; Lundström KL; Koyi H; Brandén E; Larsson O; Bergqvist M
Article: CLINICAL CANCER RESEARCH. 2015;21(4):864-869

Recurrent PRDM10 Gene Fusions in Undifferentiated Pleomorphic Sarcoma

Hofvander J; Tayebwa J; Nilsson J; Magnusson L; Brosjo O; Larsson O; von Steyern FV; Mandahl N; Fletcher CDM; Mertens F
Article: ONCOTARGET. 2014;5(22):11193-11208

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic

Bieghs L; Lub S; Fostier K; Maes K; Van Valckenborgh E; Menu E; Johnsen HE; Overgaard MT; Larsson O; Axelson M; Nyegaard M; Schots R; Jernberg-Wiklund H; Vanderkerken K; De Bruyne E
Article: ONCOGENE. 2014;33(42):5006-5016

SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma

Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
Article: ONCOTARGET. 2014;5(18):8379-8392

Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism

Waraky A; Akopyan K; Parrow V; Stroemberg T; Axelson M; Abrahmsen L; Lindqvist A; Larsson O; Aleem E
Article: INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY. 2014;53:475-481

Fusions involving protein kinase C and membrane-associated proteins in benign fibrous histiocytoma

Plaszczyca A; Nilsson J; Magnusson L; Brosjo O; Larsson O; von Steyern FV; Domanski HA; Lilljebjorn H; Fioretos T; Tayebwa J; Mandahl N; Nord KH; Mertens F
Article: GENES CHROMOSOMES & CANCER. 2013;52(10):873-886

Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor

Mohajeri A; Tayebwa J; Collin A; Nilsson J; Magnusson L; von Steyern FV; Brosjo O; Domanski HA; Larsson O; Sciot R; Debiec-Rychter M; Hornick JL; Mandahl N; Nord KH; Mertens F
Article: CANCER RESEARCH. 2013;73(8):2518-2528

SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells

Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
Article: CIRCULATION RESEARCH. 2013;112(2):236-245

Local Control of Nuclear Calcium Signaling in Cardiac Myocytes by Perinuclear Microdomains of Sarcolemmal Insulin-Like Growth Factor 1 Receptors

Ibarra C; Vicencio JM; Estrada M; Lin Y; Rocco P; Rebellato P; Munoz JP; Garcia-Prieto J; Quest AFG; Chiong M; Davidson SM; Bulatovic I; Grinnemo K-H; Larsson O; Szabadkai G; Uhlen P; Jaimovich E; Lavandero S
Article: AMERICAN JOURNAL OF PATHOLOGY. 2012;181(3):1069-1077

Recurrent Rearrangement of the PHF1 Gene in Ossifying Fibromyxoid Tumors

Gebre-Medhin S; Nord KH; Moeller E; Mandahl N; Magnusson L; Nilsson J; Jo VY; von Steyern FV; Brosjo O; Larsson O; Domanski HA; Sciot R; Debiec-Rychter M; Fletcher CDM; Mertens F
Article: CLINICAL CANCER RESEARCH. 2012;18(8):2230-2239

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin

Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Osterborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2012;40(4):1251-1258

Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications

Feng X; Aleem E; Lin Y; Axelson M; Larsson O; Stromberg T
Article: INTERNATIONAL JOURNAL OF CANCER. 2012;130(5):1120-1127

Nuclear HER3 is associated with favorable overall survival in uveal melanoma

Trocme E; Mougiakakos D; Johansson CC; All-Eriksson C; Economou MA; Larsson O; Seregard S; Kiessling R; Lin Y
Article: EMBO REPORTS. 2012;13(3):244-250

Nuclear IGF1R is a transcriptional co-activator of LEF1/TCF

Warsito D; Sjostrom S; Andersson S; Larsson O; Sehat B
Article: INTERNATIONAL JOURNAL OF CANCER. 2011;129(7):1564-1575

Phosphatidylinositol-3′-kinase/AKT signaling is essential in synovial sarcoma

Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
Article: PATHOLOGY INTERNATIONAL. 2011;61(9):536-538

Solitary fibrous tumor of the prostate: A report of two cases

Talvitie H; Astrom K; Larsson O; Ahlen J; Bergh A; Egevad L
Article: PLOS ONE. 2011;6(3):e14757

Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP)

Hashemi J; Worrall C; Vasilcanu D; Fryknas M; Sulaiman L; Karimi M; Weng W-H; Lui W-O; Rudduck C; Axelson M; Jernberg-Wiklund H; Girnita L; Larsson O; Larsson C
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2011;404(2):667-671

Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9

Deng H; Lin Y; Badin M; Vasilcanu D; Stromberg T; Jernberg-Wiklund H; Sehat B; Larsson O
Article: INTERNATIONAL JOURNAL OF CANCER. 2010;126(11):2682-2689

Expression and prognostic significance of iNOS in uveal melanoma

Johansson CC; Mougiakakos D; Trocme E; All-Ericsson C; Economou MA; Larsson O; Seregard S; Kiessling R
Article: FERTILITY AND STERILITY. 2010;93(8):2621-2626

Selective insulin-like growth factor-I antagonist inhibits mouse embryo development in a dose-dependent manner

Inzunza J; Danielsson O; Lalitkumar PG; Larsson O; Axelson M; Tohonen V; Danielsson KG; Stavreus-Evers A
Article: CANCER. 2010;116(9):2224-2233

Intratumoral Forkhead Box P3-Positive Regulatory T Cells Predict Poor Survival in Cyclooxygenase-2 Positive Uveal Melanoma

Mougiakakos D; Johansson CC; Trocme E; All-Ericsson C; Economou MA; Larsson O; Seregard S; Kiessling R
Article: SCIENCE SIGNALING. 2010;3(108):ra10

SUMOylation Mediates the Nuclear Translocation and Signaling of the IGF-1 Receptor

Sehat B; Tofigh A; Lin Y; Trocme E; Liljedahl U; Lagergren J; Larsson O
Article: NEURO-ONCOLOGY. 2010;12(1):19-27

Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma

Yin S; Girnita A; Stromberg T; Khan Z; Andersson S; Zheng H; Ericsson C; Axelson M; Nister M; Larsson O; Ekstrom TJ; Girnita L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2009;387(1):36-41

Focal adhesion kinase (FAK) activates and stabilizes IGF-1 receptor

Andersson S; D'Arcy P; Larsson O; Sehat B
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(8):1458-1467

Aberrant intracellular IGF-1R β-subunit makes receptor knockout cells (IGF1R^-/-) susceptible to oncogenic transformation

Natalishvili N; Axelson M; Girnita L; Larsson O; Vasilcanu D
Article: JOURNAL OF PATHOLOGY. 2008;216(4):428-439

Insulin-like growth factor-I receptor acts as a growth regulator in synovial sarcoma

Friedrichs N; Kuechler J; Enl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:42-49

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.

Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:35-41

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.

Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:26-34

The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.

Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: ACTA OPHTHALMOLOGICA. 2008;46:20-25

Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma. Intercorrelation and prognostic implications

Economou MA; Ericsson CA; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
Article: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2008;130(3):375-381

Quantitative assessment of the subepithelial collagen band does not increase the accuracy of diagnosis of collagenous colitis

Rubio CA; Orrego A; Hoog A; Porwitz A; F'etersson F; Elmberger G; Glaessgen A; Eriksson E; Kanter L; Jaremko G; Egevad L; Laforga J; Liljefors M; Lofdahl B; Norman P; Larsson O; Wanat R; Wejde J; Zickert P; Bjork J; Caini S; Palli D; Nesi G
Article: CANCER RESEARCH. 2008;68(14):5669-5677

Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis

Sehat B; Andersson S; Girnita L; Larsson O
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2008;49(6):2620-2626

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor

Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2008;49(6):2337-2342

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma

Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: ONCOGENE. 2008;27(11):1629-1638

Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor:: potential mechanistic involvement of Mdm2 and β-arrestin1

Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
Article: INTERNATIONAL JOURNAL OF CANCER. 2007;121(8):1857-1861

Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival

Menu E; Jernberg-Wiklund H; De Raeve H; De Leenheer E; Coulton L; Gallagher O; Van Valckenborgh E; Larsson O; Axelson M; Nilsson K; Van Camp B; Croucher P; Vanderkerken K
Article: JOURNAL OF VASCULAR SURGERY. 2007;46(1):108-115

The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling

Razuvaev A; Henderson B; Girnita L; Larsson O; Axelson M; Hedin U; Roy J
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2007;282(15):11329-11338

β-Arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression

Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Vasilcanu D; Girnita A; Lefkowitz RJ; Larsson O
Article: PLOS ONE. 2007;2(4):e340

Role of Ubiquitination in IGF-1 Receptor Signaling and Degradation

Sehat B; Andersson S; Vasilcanu R; Girnita L; Larsson O
Article: ENDOCRINE-RELATED CANCER. 2007;14(1):125-134

The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma

Geli J; Kiss N; Lanner F; Foukakis T; Natalishvili N; Larsson O; Kogner P; Hoog A; Clark GJ; Ekstrom TJ; Backdahl M; Farnebo F; Larsson C
Article: BRITISH JOURNAL OF CANCER. 2007;96 Suppl:R2-R6

Role of insulin-like growth factor 1 receptor signalling in cancer.

Larsson O; Girnita A; Girnita L
Article: ENDOCRINOLOGY. 2007;148(1):128-139

Insulin-like growth factor-I is an important antiapoptotic factor for rat Leydig cells during postnatal development

Colon E; Zaman F; Axelson M; Larsson O; Carlsson-Skwirut C; Svechnikov KV; Soder O
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2006;347(4):1059-1066

IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-)

Rosengren L; Vasilcanu D; Vasilcanu R; Fickenscher S; Sehat B; Natalishvili N; Naughton S; Yin S; Girnita A; Girnita L; Axelson M; Larsson O
Article: LANCET ONCOLOGY. 2006;7(7):605-607

A 10-year-old girl with bifocal synovial sarcoma

Weng W-H; Claviez A; Krams M; Hashemi J; Larsson O; Larsson C; Suttorp M
Article: ONCOGENE. 2006;25(22):3186-3195

The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection

Vasilcanu D; Weng W-H; Girnita A; Lui W-O; Vasilcanu R; Axelson M; Larsson O; Larsson C; Girnita L
Article: CLINICAL CANCER RESEARCH. 2006;12(4):1383-1391

The insulin-like growth factor-1 receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells

Girnita A; All-Ericsson C; Economou MA; Åström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: BLOOD. 2006;107(2):655-660

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model

Menu E; Jernberg-Wiklund H; Stromberg T; De Raeve H; Girnita L; Larsson O; Axelson M; Asosingh K; Nilsson K; Van Camp B; Vanderkerken K
Article: BLOOD. 2006;107(2):669-678

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G₂/M-phase accumulation and apoptosis in multiple myeloma cells

Strömberg T; Ekman S; Girnita L; Dimberg LY; Larsson O; Axelson M; Lennartsson J; Hellman U; Carlson K; Österborg A; Vanderkerken K; Nilsson K; Jernberg-Wiklund H
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2005;46(12):4372-4375

Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: Intercorrelation and prognostic implications

Economou MA; All-Ericsson C; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
Article: CLINICAL CANCER RESEARCH. 2005;11(13):4674-4680

Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells:: A novel therapeutic approach

Ulfarsson E; Karström A; Yin SC; Girnita A; Vasilcanu D; Thoren M; Kratz G; Hillman J; Axelson M; Larsson O; Girnita L
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2005;280(26):24412-24419

β-arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase

Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Girnita A; Lefkowitz RJ; Larsson O
Article: JOURNAL OF CELLULAR PHYSIOLOGY. 2005;203(1):27-34

Changes in cell shape and anchorage in relation to the restriction point

Martinsson HS; Zickert P; Starborg M; Larsson O; Zetterberg A
Article: CLINICAL CANCER RESEARCH. 2005;11(1):206-216

Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma

Åhlén J; Wejde J; Brosjö O; von Rosen A; Weng WH; Girnita L; Larsson O; Larsson C
Article: ONCOGENE. 2004;23(47):7854-7862

The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway

Vasilcanu D; Girnita A; Girnita L; Vasilcanu R; Axelson M; Larsson O
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2004;45(7):2075-2082

c-Kit-dependent growth of uveal melanoma cells:: A potential therapeutic target?

All-Ericsson C; Girnita L; Müller-Brunotte A; Brodin B; Seregard S; Östman A; Larsson O
Article: DIAGNOSTIC MOLECULAR PATHOLOGY. 2004;13(1):47-51

A novel case of synovial sarcoma of the kidney:: Impact of SS18/SSX analysis of renal hemangiopericytoma-like tumors

Törnkvist M; Wejde J; Åhlén J; Brodin B; Larsson O
Article: CANCER RESEARCH. 2004;64(1):236-242

Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth

Girnita A; Girnita L; del Prete F; Bartolazzi A; Larsson O; Axelson M
Article: ONCOGENE. 2003;22(48):7628-7631

Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene (Publication with Expression of Concern)

Xie YT; Törnkvist M; Aalto Y; Nilsson G; Girnita L; Nagy B; Knuutila S; Larsson O
Article: ONCOLOGY REPORTS. 2003;10(5):1641-1645

Evaluation of immunohistochemical parameters as prognostic markers in malignant fibrous histiocytoma

Åhlén J; Weng WWH; Brosjö O; Von Rosen A; Larsson O; Larsson C
Article: BRITISH JOURNAL OF CANCER. 2003;89(4):720-726

Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis

Weng WH; Åhlén J; Lui WO; Brosjö O; Pang ST; von Rosen A; Auer G; Larsson O; Larsson C
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2003;100(14):8247-8252

Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor

Girnita L; Girnita A; Larsson O
Article: ONCOGENE. 2003;22(14):2215-2222

Characteristic sequence motifs located at the genomic breakpoints of the translocation t(X;18) in synovial sarcomas

Wei YK; Sun MH; Nilsson G; Dwight T; Xie YT; Wang J; Hou YY; Larsson O; Larsson C; Zhu XZ
Article: ONCOGENE. 2002;21(37):5791-5796

The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1.: A link between t(X;18)(p11. 2; q11.2) and the cell cycle machinery

Xie YT; Skytting B; Nilsson G; Grimer RJ; Mangham CD; Fisher C; Shipley J; Bjerkehagen B; Myklebost O; Larsson O
Article: BRITISH JOURNAL OF CANCER. 2002;87(4):414-422

Tissue distribution and differential expression of melanocortin I receptor, a malignant melanoma marker

Salazar-Onfray F; López M; Lundqvist A; Aguirre A; Escobar A; Serrano A; Korenblit C; Petersson M; Chhajlani V; Larsson O; Kiessling R
Article: CANCER RESEARCH. 2002;62(13):3861-3867

SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: A gain of function of the t(X;18)(p11.2;q11.2) translocation

Xie YT; Skytting B; Nilsson G; Gasbarri A; Haslam K; Bartolazzi A; Brodin B; Mandahl N; Larsson O
Article: ONCOGENE. 2002;21(26):4181-4190

Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas

Yang K; Lui WO; Xie YT; Zhang AJ; Skytting B; Mandahl N; Larsson C; Larsson O
Article: INTERNATIONAL JOURNAL OF CANCER. 2002;99(4):560-567

Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses

Panagopoulos I; Mertens F; Dêbiec-Rychter M; Isaksson M; Limon J; Kardas I; Domanski HA; Sciot R; Perek D; Crnalic S; Larsson O; Mandahl N
Article: MODERN PATHOLOGY. 2002;15(6):679-685

A novel type of SYT/SSX fusion:: Methodological and biological implications

Törnkvist M; Brodin B; Bartolazzi A; Larsson O
Article: GENES CHROMOSOMES & CANCER. 2002;33(2):188-200

Cytogenetic aberrations and their prognostic impact in chondrosarcoma

Mandahl N; Gustafson P; Mertens F; Åkerman M; Baldetorp B; Gisselsson D; Knuutila S; Bauer HCF; Larsson O
Article: CANCER RESEARCH. 2002;62(1):135-140

Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: A multi-institutional retrospective study of 243 patients

Ladanyi M; Antonescu CR; Leung DH; Woodruff JM; Kawai A; Healey JH; Brennan MF; Bridge JA; Neff JR; Barr FG; Goldsmith JD; Brooks JSJ; Goldblum JR; Ali SZ; Shipley J; Cooper CS; Fisher C; Skytting B; Larsson O
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2002;43(1):1-8

Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target

All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Article: ACTA ONCOLOGICA. 2002;41(2):138-146

Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994

Mansson-Brahme E; Johansson H; Larsson O; Rutqvist LE; Ringborg U
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2001;288(3):736-741

Characterization of hydrophobic prenyl groups of isoprenylated proteins in human cancer cells

Hjertman M; Wejde J; Larsson O
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2001;42(10):2153-2156

Association of HLA class I and class II antigen expression and mortality in uveal melanoma

Ericsson C; Seregard S; Bartolazzi A; Levitskaya E; Ferrone S; Kiessling R; Larsson O
Article: GENES CHROMOSOMES & CANCER. 2001;31(4):362-372

Clinical impact of molecular and cytogenetic findings in synovial sarcoma

Panagopoulos I; Mertens F; Isaksson M; Limon J; Gustafson P; Skytting B; Åkerman M; Sciot R; Dal Cin P; Samson I; Iliszko M; Ryoe J; Dêbiec-Rychter M; Szadowska A; Brosjö O; Larsson O; Rydholm A; Mandahl N
Article: LANCET. 2001;357(9269):1644-1650

Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions

Bartolazzi A; Gasbarri A; Papotti M; Bussolati G; Lucante T; Khan A; Inohara H; Marandino F; Orlandi F; Nardi F; Vecchione A; Tecce R; Larsson O
Article: GENE. 2001;268(1-2):173-182

Cloning and characterization of spliced fusion transcript variants of synovial sarcoma: SYT/SSX4, SYT/SSX4v, and SYT/SSX2v. Possible regulatory role of the fusion gene product in wild type SYT expression

Brodin B; Haslam K; Yang K; Bartolazzi A; Xie YT; Starborg M; Lundeberg J; Larsson O
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2001;42(2):313-317

Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma

Aalto Y; Eriksson L; Seregard S; Larsson O; Knuutila S
Article: SARCOMA. 2001;5(3):143-149

Malignant Fibrous Histiocytoma, Aggressive Fibromatosis and Benign Fibrous Tumors Express mRNA for the Metalloproteinase Inducer EMMPRIN and the Metalloproteinases MMP-2 and MT1-MMP.

Ahlén J; Enberg U; Larsson C; Larsson O; Frisk T; Brosjö O; Rosen A; Bäckdahl M
Article: CANCER RESEARCH. 2000;60(18):5278-5283

Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: Functional impact

Girnita L; Girnita A; Brodin B; Xie YT; Nilsson G; Dricu A; Lundeberg J; Wejde J; Bartolazzi A; Wiman KG; Larsson O
Article: LARYNGOSCOPE. 2000;110(9):1498-1504

A prospective population-based study of cutaneous malignant melanoma of the head and neck

Gillgren P; Månsson-Brahme E; Frisell J; Johansson H; Larsson O; Ringborg U
Article: ONCOGENE. 2000;19(37):4298-4301

A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells

Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
Article: MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2000;165(1-2):131-137

Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway

Kanter-Lewensohn L; Girnita L; Girnita A; Dricu A; Olsson G; Leech L; Nilsson G; Hilding A; Wejde J; Brismar K; Larsson O
Article: CANCER. 2000;89(2):348-355

Trends in mortality from malignant melanoma in Sweden, 1970-1996

Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Johansson H; Ringborg U
Article: ONCOLOGY RESEARCH. 2000;15(1):67-72

Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications

Girnita L; Wang M; Xie YT; Nilsson G; Dricu A; Wejde J; Larsson O
Article: GROWTH FACTORS. 2000;17(3):193-202

Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27^Kip1 in melanocytic tumors:: A potential regulatory role of IGF-1 pathway in distribution of p27^Kip1 between different cyclins

Kanter-Lewensohn L; Dricu A; Girnita L; Wejde J; Larsson O
Article: ACTA ORTHOPAEDICA. 1999;70(6):543-554

Synovial sarcoma -: identification of favorable and unfavorable histologic types -: A Scandinavian sarcoma group study of 104 cases

Skytting B; Meis-Kindblom JM; Larsson O; Virolainen M; Perfekt R; Åkerman M; Kindblom LG
Article: ACTA RADIOLOGICA. 1999;40(6):603-609

110 subfascial lipomatous tumors -: MR and CT findings versus histopathological diagnosis and cytogenetic analysis

Einarsdottir H; Söderlund V; Larsson O; Mandahl N; Bauer HCF
Article: CANCER GENETICS. 1999;115(1):39-46

Clinical importance of genomic imbalances in synovial sarcoma evaluated by comparative genomic hybridization

Skytting BT; Szymanska J; Aalto Y; Lushnikova T; Blomqvist C; Elomaa I; Larsson O; Knuutila S
Article: BRITISH JOURNAL OF CANCER. 1999;80(11):1809-1814

Ki-67 is strongly prognostic in synovial sarcoma: analysis based on 86 patients from the Scandinavian Sarcoma Group Register

Skytting BT; Bauer HC; Perfekt R; Nilsson G; Larsson O
Article: CANCER RESEARCH. 1999;59(15):3588-3591

Expression of insulin-like growth factor-1 receptor in synovial sarcoma: Association with an aggressive phenotype

Xie YT; Skytting B; Nilsson G; Brodin B; Larsson O
Article: JOURNAL OF IMMUNOLOGY. 1999;163(2):1037-1044

Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas

Yang RC; Salazar-Onfray F; Charo J; Malmberg KJ; Evrin K; Maes H; Kono K; Hising C; Petersson M; Larsson O; Lan L; Appella E; Sette A; Celis E; Kiessling R
Article: CANCER RESEARCH. 1999;59(13):3180-3184

The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome

Nilsson G; Skytting B; Xie YT; Brodin B; Perfekt R; Mandahl N; Lundeberg J; Uhlén M; Larsson O
Article: ACTA ORTHOPAEDICA SCANDINAVICA, SUPPLEMENT. 1999;70:47-49

Diagnosis, treatment and prognosis of patients with synovial sarcoma - The Scandinavian Sarcoma Group experience

Skytting BT; Bauer HCF; Larsson O
Article: GLYCOBIOLOGY. 1999;9(6):571-579

Expression of the insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway

Dricu A; Kanter L; Wang M; Nilsson G; Hjertman M; Wejde J; Larsson O
Article: EXPERIMENTAL CELL RESEARCH. 1999;246(1):38-46

Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells

Wang M; Xie YT; Girnita L; Nilsson G; Dricu A; Wejde J; Larsson O
Article: SARCOMA. 1999;3(1):25-32

Detection of EWS/FLI-1 by Immunostaining. An Adjunctive Tool in Diagnosis of Ewing's Sarcoma and Primitive Neuroectodermal Tumour on Cytological Samples and Paraffin-Embedded Archival Material.

Nilsson G; Wang M; Wejde J; Kreicbergs A; Larsson O
Article: ACTA ONCOLOGICA. 1999;38(5):549-557

Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma

Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Singnomklao T; Ringborg U
Article: ACTA ONCOLOGICA. 1999;38(8):1069-1074

Epidemiological characteristics of cutaneous malignant melanoma of the head and neck -: A population-based study

Gillgren P; Månsson-Brahme E; Frisell J; Johansson H; Larsson O; Ringborg U
Article: JOURNAL OF CELLULAR BIOCHEMISTRY. 1998;71(4):502-514

Dolichol-like lipids with stimulatory effect on DNA synthesis:: Substrates for protein dolichylation?

Wejde J; Hjertman M; Carlberg M; Egestad B; Griffiths WJ; Sjövall J; Larsson O
Article: ACTA CYTOLOGICA. 1998;42(6):1317-1324

Reverse transcriptase polymerase chain reaction on fine needle aspirates for rapid detection of translocations in synovial sarcoma

Nilsson G; Wang M; Wejde J; Kanter L; Karlén J; Tani E; Kreicbergs A; Larsson O
Article: GENES CHROMOSOMES & CANCER. 1998;23(3):213-219

Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization

Szymanska J; Serra M; Skytting B; Larsson O; Virolainen M; Akerman M; Tarkkanen M; Huuhtanen R; Picci P; Bacchini P; Asko-Seljavaara S; Elomaa I; Knuutila S
Article: MELANOMA RESEARCH. 1998;8(5):389-397

Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target

Kanter-Lewensohn L; Dricu A; Wang M; Wejde J; Kiessling R; Larsson O
Article: JOURNAL OF PATHOLOGY. 1998;185(1):112-115

Inflammatory leiomyosarcoma may be characterized by specific near-haploid chromosome changes

Dal Cin P; Sciot R; Fletcher CDM; Samson I; De Vos R; Mandahl N; Willén H; Larsson O; Van den Berghe H
Article: CANCER GENETICS. 1998;102(1):59-64

Unbalanced chromosomal rearrangements in a metastasizing salivary gland tumor with benign histology

Jin YS; Jin C; Arheden K; Larsson O; Bauer HFC; Mandahl N; Mertens F
Article: VIRCHOWS ARCHIV. 1998;432(2):131-134

Specific and sensitive detection of the EWS/FLI1 fusion protein in Ewing's sarcoma by Western blotting

Wang M; Nilsson G; Carlberg M; Dricu A; Wejde J; Kreicbergs A; Larsson O
Article: ACTA ONCOLOGICA. 1998;37(5):463-470

Central nervous system metastases of cutaneous malignant melanoma -: A population-based study

Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Johansson H; Ringborg U
Article: FEBS LETTERS. 1997;416(3):235-238

Evidence for protein dolichylation

Hjertman M; Wejde J; Dricu A; Carlberg M; Griffiths WJ; Sjovall J; Larsson O
Article: MODERN PATHOLOGY. 1997;10(9):917-920

Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas

KanterLewensohn L; Hedblad MA; Wejde J; Larsson O
Article: GLYCOBIOLOGY. 1997;7(5):625-633

Mevalonate-regulated mechanisms in cell growth control: Role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc

Dricu A; Wang M; Hjertman M; Malec M; Blegen H; Wejde J; Carlberg M; Larsson O
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1997;24(5):511-515

Use of Tc-99m-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy

Soderlund V; Larsson SA; Bauer HCF; Brosjo O; Larsson O; Jacobsson H
Article: CANCER RESEARCH. 1997;57(3):543-548

Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: Role of down-regulation of the insulin like growth factor 1 receptor in induction of apoptosis

Dricu A; Carlberg M; Wang M; Larsson O
Article: CARCINOGENESIS. 1996;17(12):2589-2596

Short exposures to tunicamycin induce apoptosis in SV40-transformed but not in normal human fibroblasts

Carlberg M; Dricu A; Blegen H; Kass GEN; Orrenius S; Larsson O
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1996;271(29):17453-17462

Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface - Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth

Carlberg M; Dricu A; Blegen H; Wang M; Hjertman M; Zickert P; Hoog A; Larsson O
Article: BIOCHEMICAL PHARMACOLOGY. 1996;52(1):127-131

Expression of the low-density lipoprotein receptor, HMG-CoA reductase, and multidrug resistance (Mdr1) genes in colorectal carcinomas

Vitols S; Gunven P; Gruber A; Larsson O
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1996;271(22):12724-12736

27-Hydroxylated low density lipoprotein (LDL) cholesterol can be converted to 7 alpha,27-dihydroxy-4-cholesten-3-one (cytosterone) before suppressing cholesterol production in normal human fibroblasts - Evidence that an altered metabolism of LDL cholesterol can underlie a defective feedback control in malignant cells

Axelson M; Larsson O
Article: RAPID COMMUNICATIONS IN MASS SPECTROMETRY. 1996;10(6):663-675

Analysis of dolichols and polyprenols and their derivatives by electron impact, fast atom bombardment and electrospray ionization tandem mass spectrometry

Griffiths WJ; Hjertman M; Lundsjo A; Wejde J; Sjovall J; Larsson O
Article: EXPERIMENTAL CELL RESEARCH. 1996;223(1):142-148

Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-1 receptors in human fibroblasts

Carlberg M; Larsson O
Article: CURRENT OPINION IN CELL BIOLOGY. 1995;7(6):835-842

WHAT IS THE RESTRICTION POINT

ZETTERBERG A; LARSSON O; WIMAN KG
Article: MELANOMA RESEARCH. 1995;5(5):345-350

UTILITY OF A PROLIFERATION MARKER IN DISTINGUISHING BETWEEN BENIGN NEVOCELLULAR NEVI AND NEVOCELLULAR NEVUS-LIKE LESIONS WITH MALIGNANT PROPERTIES

KANTER L; BLEGEN H; WEJDE J; LAGERLOF B; LARSSON O
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1995;270(25):15102-15110

LOW-DENSITY-LIPOPROTEIN (LDL) CHOLESTEROL IS CONVERTED TO 27-HYDROXYCHOLESTEROL IN HUMAN FIBROBLASTS - EVIDENCE THAT 27-HYDROXYCHOLESTEROL CAN BE AN IMPORTANT INTRACELLULAR MEDIATOR BETWEEN LDL AND THE SUPPRESSION OF CHOLESTEROL PRODUCTION

AXELSON M; LARSSON O
Article: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 1995;1256(3):353-359

7-ALPHA-HYDROXYLATION OF 25-HYDROXYCHOLESTEROL AND 27-HYDROXYCHOLESTEROL IN HUMAN FIBROBLASTS

ZHANG J; LARSSON O; SJOVALL J
Article: JOURNAL OF LIPID RESEARCH. 1995;36(2):290-298

STRUCTURAL SPECIFICITY IN THE SUPPRESSION OF HMG-COA REDUCTASE IN HUMAN FIBROBLASTS BY INTERMEDIATES IN BILE-ACID BIOSYNTHESIS

AXELSON M; LARSSON O; ZHANG J; SHODA J; SJOVALL J
Article: CELL PROLIFERATION. 1995;28(1):33-43

EXISTENCE OF A COMMITMENT PROGRAM FOR MITOSIS IN EARLY G(1) IN TUMOR-CELLS

LARSSON O; ZETTERBERG A
Article: CANCER BIOCHEMISTRY BIOPHYSICS. 1995;14(4):243-256

EFFECT OF VIRUS-TRANSFORMATION AND GROWTH-FACTOR STIMULATION ON ISOPRENE BIOSYNTHESIS IN HUMAN FIBROBLASTS - A CORRELATION TO CELL-GROWTH

LARSSON O
Show more

All other publications

Corrigendum: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2023;16(1):61

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK⁺ T-cell lymphoma (vol 12, 80, 2019)

George B; George SK; Shi W; Haque A; Shi P; Eskandari G; Axelson M; Larsson O; Kaseb AO; Amin HM
Meeting abstract: JOURNAL OF VASCULAR SURGERY. 2010;51:72S-73S

A Specific Inhibitor of IGF-1 Receptor - Picropodophyllin Can Suppress Atheroma Progression and Has a Stabilizing Effect on Atherosclerotic Lesions in ApoE Deficient Mice

Razuvaev A; Larsson O; Axelson M; Hedin U; Roy J
Letter: CANCER RESEARCH. 2007;67(6):2899-2900

Cyclolignans as inhibitors of the insulin-like growth factor-I receptor

Larsson O; Axelson M
Review: BRITISH JOURNAL OF CANCER. 2005;92(12):2097-2101

Role of insulin-like growth factor 1 receptor signalling in cancer

Larsson O; Girnita A; Girnita L
Meeting abstract: BLOOD. 2004;104(11):184A-185A

Targeting the insulin-like growth factor-i receptor (IGF-IR) in multiple myeloma cells using selective IGF-IR tyrosine kinase inhibitors.

Stromberg T; Ekman S; Girnita L; Lennartsson J; Hellman U; Carlson K; Osterborg A; Vanderkerken K; Axelson M; Larsson O; Jernberg-Wiklund H
Meeting abstract: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2004;50(3):P117

Possible use of flavonoids as cell growth inhibitors in malignant melanoma

Girnita A; Girnita L; Axelson M; Larsson O
Letter: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2001;93(17):1348-1349

Re:: A novel fusion gene, SYT-SSX4, in synovial sarcoma -: Responce

Brodin B; Törnkvist M; Haslam K; Xie Y; Bartolazzi A; Larsson O
Letter: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1999;91(11):974-975

A novel fusion gene, SYT-SSX4, in synovial sarcoma

Skytting B; Nilsson G; Brodin B; Xie YT; Lundeberg J; Uhlén M; Larsson O
Letter: MELANOMA RESEARCH. 1999;9(3):304

Nodular histogenetic type - the most significant factor for thick melanoma: implications for prevention. Response

Bergenmar M; Ringborg U; Brahme EM; Brandberg Y; Larsson O
Review: ACTA ORTHOPAEDICA SCANDINAVICA, SUPPLEMENT. 1999;70:18-26

Morphologic review of 1000 soft tissue sarcomas from the Scandinavian Sarcoma Group (SSG) Register -: The peer-review committee experience

Meis-Kindblom JM; Bjerkehage B; Böhling T; Domanski H; Halvorsen TB; Larsson O; Lilleng P; Myhre-Jensen O; Stenwig E; Virolainen M; Willén H; Åkerman M; Kindblom LG
Published conference paper: ACTA ONCOLOGICA. 1999;38(7):971-972

Interferon-induced remission in aggressive fibromatosis of the lower extremity

Fernberg JO; Brosjö O; Larsson O; Söderlund V; Strander H
Published conference paper: CANCER. 1997;80(8):1418-1425

Outcomes of patients with local recurrence of cutaneous malignant melanoma - A population-based study

CohnCedermark G; ManssonBrahme E; Rutqvist LE; Larsson O; Singnomklao T; Ringborg U
Letter: JOURNAL OF MASS SPECTROMETRY. 1997;32(8):899-903

Tandem mass spectrometry of geranylgeranylcysteine

Griffiths WJ; Hjertman M; Wejde J; Larsson O; Sjovall J
Review: LAKARTIDNINGEN. 1997;94(28-29):2545-2547

[Melanocytic tumors. Liberal nevus surgery and histopathological scrutiny reduce mortality].

Larsson O; Ringborg U
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 1996;22(3):197-212

HMG-CoA reductase inhibitors: Role in normal and malignant cells

Larsson O

Articles

All other publications

News from KI

Events from KI